773490004: Allergy to dihydroergotamine (finding)

• SNOMED CT Concept\Clinical finding (finding)\...
• \The disposition to develop an allergic or pseudoallergic reaction, the reaction itself or its consequences.\A propensity to developing an adverse reaction upon exposure to an agent at a dose otherwise tolerated by normal individuals. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to drug\Allergy to ergot alkaloid (finding)\Allergy to dihydroergotamine
• \The disposition to develop an allergic or pseudoallergic reaction, the reaction itself or its consequences.\A propensity to developing an adverse reaction upon exposure to an agent at a dose otherwise tolerated by normal individuals. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to drug\Allergy to ergoline derivative (finding)\Allergy to dihydroergotamine
• \The disposition to develop an allergic or pseudoallergic reaction, the reaction itself or its consequences.\A propensity to developing an adverse reaction upon exposure to an agent at a dose otherwise tolerated by normal individuals. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to drug\Allergy to alpha adrenergic receptor agonist (finding)\Allergy to dihydroergotamine
• \The disposition to develop an allergic or pseudoallergic reaction, the reaction itself or its consequences.\The disposition to develop an allergic reaction, the allergic reaction itself or its consequences.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to drug\Allergy to ergot alkaloid (finding)\Allergy to dihydroergotamine
• \The disposition to develop an allergic or pseudoallergic reaction, the reaction itself or its consequences.\The disposition to develop an allergic reaction, the allergic reaction itself or its consequences.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to drug\Allergy to ergoline derivative (finding)\Allergy to dihydroergotamine
• \The disposition to develop an allergic or pseudoallergic reaction, the reaction itself or its consequences.\The disposition to develop an allergic reaction, the allergic reaction itself or its consequences.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to drug\Allergy to alpha adrenergic receptor agonist (finding)\Allergy to dihydroergotamine
• \Propensity to adverse reaction\A propensity to developing an adverse reaction upon exposure to an agent at a dose otherwise tolerated by normal individuals. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to drug\Allergy to ergot alkaloid (finding)\Allergy to dihydroergotamine
• \Propensity to adverse reaction\A propensity to developing an adverse reaction upon exposure to an agent at a dose otherwise tolerated by normal individuals. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to drug\Allergy to ergoline derivative (finding)\Allergy to dihydroergotamine
• \Propensity to adverse reaction\A propensity to developing an adverse reaction upon exposure to an agent at a dose otherwise tolerated by normal individuals. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to drug\Allergy to alpha adrenergic receptor agonist (finding)\Allergy to dihydroergotamine
• \Propensity to adverse reaction\Propensity to adverse reactions to drug\Allergy to drug\Allergy to ergot alkaloid (finding)\Allergy to dihydroergotamine
• \Propensity to adverse reaction\Propensity to adverse reactions to drug\Allergy to drug\Allergy to ergoline derivative (finding)\Allergy to dihydroergotamine
• \Propensity to adverse reaction\Propensity to adverse reactions to drug\Allergy to drug\Allergy to alpha adrenergic receptor agonist (finding)\Allergy to dihydroergotamine

Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2019. Module: SNOMED CT core

Descriptions:

Id	Description	Lang	Type	Status	Case?	Module
3723697019	Dihydroergotamine allergy	en	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
3749099016	Allergy to dihydroergotamine	en	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
3749127011	Allergy to dihydroergotamine (finding)	en	Fully specified name	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
366131000195111	allergia alla diidroergotamina	it	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT Switzerland NRC maintained Module
1129621000241110	allergie à la dihydroergotamine	fr	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT Switzerland NRC maintained Module

Expanded Value Set

This concept is not in any reference sets

Back to Start